These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25877064)

  • 21. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate.
    Wynn D; Lategan TW; Sprague TN; Rousseau FS; Fox EJ
    Mult Scler Relat Disord; 2020 Oct; 45():102335. PubMed ID: 32629403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
    Prosperini L; Pontecorvo S
    Ther Clin Risk Manag; 2016; 12():339-50. PubMed ID: 27042079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis.
    Alroughani R; Huppke P; Mazurkiewicz-Beldzinska M; Blaschek A; Valis M; Aaen G; Pultz J; Peng X; Beynon V
    Front Neurol; 2020; 11():606418. PubMed ID: 33473248
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.
    Calkwood J; Vollmer T; Fox RJ; Zhang R; Novas M; Sheikh SI; Viglietta V
    Int J MS Care; 2016; 18(3):138-46. PubMed ID: 27252601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
    J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ; Gold R; Phillips JT; Okwuokenye M; Zhang A; Marantz JL
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence.
    Narapureddy B; Dubey D
    Patient Prefer Adherence; 2019; 13():1655-1666. PubMed ID: 31631980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis.
    Lager B; Liseno J; Božin I; England SM; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2023 Feb; 12(1):145-159. PubMed ID: 36334241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
    Venci JV; Gandhi MA
    Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dimethyl fumarate for relapsing MS.
    Serra A; Fox RJ
    Neurol Clin Pract; 2013 Jun; 3(3):249-253. PubMed ID: 29473631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
    Gold R; Phillips JT; Havrdova E; Bar-Or A; Kappos L; Kim N; Thullen T; Valencia P; Oliva L; Novas M; Li J; Sweetser MT; Kurukulasuriya N; Viglietta V; Fox RJ
    Neurol Ther; 2015 Dec; 4(2):93-104. PubMed ID: 26662361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethyl fumarate : a Janus-faced substance?
    Kees F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1559-67. PubMed ID: 23697607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources.
    Rodríguez-Regal A; Ramos-Rúa L; Anibarro-García L; Lopez Real AM; Amigo-Jorrín MDC
    Patient Prefer Adherence; 2021; 15():149-158. PubMed ID: 33542621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.
    Stangel M; Linker RA
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.
    Storm-Larsen C; Myhr KM; Farbu E; Midgard R; Nyquist K; Broch L; Berg-Hansen P; Buness A; Holm K; Ueland T; Fallang LE; Burum-Auensen E; Hov JR; Holmøy T
    Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319888767. PubMed ID: 31798939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2018 May; 40(5):812. PubMed ID: 29523369
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.
    Giovannoni G; Gold R; Kappos L; Arnold DL; Bar-Or A; Marantz JL; Yang M; Lee A
    Mult Scler J Exp Transl Clin; 2016; 2():2055217316634111. PubMed ID: 28607719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.